Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Prospective MRI and Neurocognitive Assessment of “Chemobrain” in Acute Myeloid Leukaemia: The Mineral Study

Ashleigh Scott, Ada Lo, Kate Thompson, Ying Xia, Harriet Bodimeade, Amir Fazlollahi, Cameron Curley, Steven W. Lane, Kirk Lachlan Morris, Caroline Jane McNamara, Elango S. Pillai, Nicholas Weber, Olivier Salvado, Katie L McMahon, Glen A Kennedy

Blood (2023) 142 (Supplement 1): 5850.

https://doi.org/10.1182/blood-2023-190301

Published: 2023

Journal Articles

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 487–488.

https://doi.org/10.1182/blood-2022-168166

Published: 2022

Journal Articles

Real-World Outcomes with CD19 CAR T-Cell Therapy for B-Cell Malignancies in Regional/Rural Australia: Results from the Queensland CAR T-Cell Program

Nilu Perera, Ashleigh P Scott, Stewart Hunt, Cameron Curley, Siok-Keen Tey, Jason Butler, Andrea S Henden, Elango S. Pillai, Cheryl Hutchins, Kari Louise Mudie, Glen A Kennedy

Blood (2022) 140 (Supplement 1): 7500–7501.

https://doi.org/10.1182/blood-2022-168399

Published: 2022

Journal Articles

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies

Michael Dickinson, Nada Hamad, Christian E Bryant, Gautam Borthakur, Chitra Hosing, David Shook, Joanne Tan, Kanya Rajangam, Hongtao Liu, Glen A Kennedy, Peter A. McSweeney, Brian T. Hill

Blood (2021) 138 (Supplement 1): 3868.

https://doi.org/10.1182/blood-2021-146602

Published: 2021

Journal Articles

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry

Edward Abadir, Jad Othman, John Kwan, David J Gottlieb, Glen A Kennedy, Ashish Bajel, Richard Doocey, Travis Perera, Anne-Marie Watson, Peter G Bardy, Matthew Greenwood, David J. Curtis, Steven Tran, John Moore, Nada Hamad

Blood (2021) 138 (Supplement 1): 2929.

https://doi.org/10.1182/blood-2021-149939

Published: 2021

Journal Articles

Early Cytomegalovirus Reactivation after Allogenic Bone Marrow Transplantation Is Associated with the Loss of Recipient-Derived Humoral Immunity and Is Reduced By IL-6 Inhibition

Ping Zhang, Peter Fleming, Christopher Andoniou, Jose Paulo Martins, Alda Saldan, Rachel Kuns, Benjamin McEnroe, Andrea S Henden, Stuart Olver, Adaeze Ekwe, Antiopi Varelias, Corey Smith, Christine R Schmidt, Kathleen S Ensbey, Michael Boeckh, Glen A Kennedy, Mariapia Degli-Esposti, Geoff R. Hill, Siok-Keen Tey

Blood (2021) 138 (Supplement 1): 648.

https://doi.org/10.1182/blood-2021-146643

Published: 2021

Journal Articles

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Blood (2021) 137 (14): 1970–1979.

https://doi.org/10.1182/blood.2020009050

Published: 2021

Includes: Supplemental data

Journal Articles

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136574

Published: 2020

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

Early Immunosuppressive Therapy for Idiopathic Pneumonia Syndrome Prior to Bronchoscopy Is Associated with Favourable Outcomes

Joseph Noye, MBBS, Glen A Kennedy, MBBS FRACP FRCPA, Ashleigh P Scott, MBBS FRACP FRCPA

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140277

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, David Gottlieb, MBBS, MD FRACP, FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Stephen R Larsen, MBBS PhDFRACP FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Simon Durrant, MBBS FRCP FRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Cameron Curley, MBBS, FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-139057

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Stephen R Larsen, MBBS PhDFRACP FRCPA, Andrew Spencer, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Simon Durrant, MBBS FRCP FRCPath, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Hugh J. Goodman, FRACP, Ian H. Kerridge, FRACP FRCPA MPhil BA, Christopher Arthur, Cameron Curley, MBBS, FRACP, FRCPA, Caroline Stewart, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Jennifer Collins, Julian Cooney, FRACP,FRCPA,MBBS,, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139076

Published: 2020

Journal Articles

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Kirsty M Sharplin, MBBS, David Ritchie, MB ChB, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Shyam Panicker, MBBS,MDMRCP,FRACP,FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Julian Cooney, FRACP,FRCPA,MBBS,, Richard Doocey, MB ChB, FRACP, FRCPA, Leanne Berkahn, MD, Sam Milliken, MBBS, FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Andrew Spencer, David J. Curtis, MBBS,PhD, Sushrut S. Patil, Stephen R Larsen, MBBS PhDFRACP FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Matthew Greenwood, MBBS, FRACP, FRCPA, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Eric Wong, MDPhD FRACP, FRCPA, Steven Tran, BEng MBiomedE, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-138684

Published: 2020

Journal Articles

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Glen A Kennedy, MBBS FRACP FRCPA, Siok-Keen Tey, MBBS,PhDFRACP,FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Ashish Misra, MBBS, FRACP, Elango Subramoniapillai, MBBS, FRACP, James Morton, MBBS, FRACP, FRCPA, Simon Durrant, FRCP,FRCPath,MBBS, Andrea S Hendon, MBBS, PhD FRACP, FRCPA, John Moore, MDFRACP,FRCPA, David Ritchie, MD PhD, David Gottlieb, MBBS, MD FRACP, FRCPA, Julian Cooney, FRACP,FRCPA,MBBS,, Luke Buizen, BSc (Hons), MSc, Sanjoy K Paul, PhD, Geoff R. Hill, MD

Blood (2019) 134 (Supplement_1): 368.

https://doi.org/10.1182/blood-2019-126285

Published: 2019

Journal Articles

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Blood (2019) 134 (Supplement_1): 5719.

https://doi.org/10.1182/blood-2019-126547

Published: 2019

Journal Articles

Targeted Molecular Imaging of Translocator Protein (TSPO) Using 18F GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD)

Ashleigh P Scott, MBBS FRACP FRCPA, Siok-Keen Tey, MBBS PhD FRACP FRCPA, Paul Thomas, MBBS FRACP FAANMS, David Pattison, MBBS MPH FRACP FAANMS, Glen A Kennedy, MBBS FRACP FRCPA

Blood (2018) 132 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2018-99-114114

Published: 2018

Journal Articles

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Doen Ming Ong, MBBS, Kathryn Jackson, MBBS, FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2512.

https://doi.org/10.1182/blood.V126.23.2512.2512

Published: 2015

NARROW

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Prospective MRI and Neurocognitive Assessment of “Chemobrain” in Acute Myeloid Leukaemia: The Mineral Study

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Real-World Outcomes with CD19 CAR T-Cell Therapy for B-Cell Malignancies in Regional/Rural Australia: Results from the Queensland CAR T-Cell Program

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry

Early Cytomegalovirus Reactivation after Allogenic Bone Marrow Transplantation Is Associated with the Loss of Recipient-Derived Humoral Immunity and Is Reduced By IL-6 Inhibition

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Early Immunosuppressive Therapy for Idiopathic Pneumonia Syndrome Prior to Bronchoscopy Is Associated with Favourable Outcomes

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Targeted Molecular Imaging of Translocator Protein (TSPO) Using 18F GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD)

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only